GLP-1 Drugs Linked to Lower Dementia Risk
GLP-1 Drugs Linked to Lower Dementia Risk
GLP-1 Drugs Linked to Lower Dementia Risk
Key points
اہم نکات
मुख्य बातें
- Popular weight-loss drugs are linked to a lower risk of dementia, but a major trial found they did not slow Alzheimer's disease once it had started.
- A review in the journal Science, by researchers from the University of Gothenburg and the University of Copenhagen, found large patient records tie GLP-1 drugs such as semaglutide and tirzepatide to fewer dementia diagnoses.
- Yet in Novo Nordisk's EVOKE and EVOKE+ phase 3 trials, semaglutide did not slow Alzheimer's itself, cutting nerve-damage markers by only about 10 percent against about 30 percent for drugs proven to slow the disease.
- Popular weight-loss drugs are linked to a lower risk of dementia, but a major trial found they did not slow Alzheimer's disease once it had started.
- A review in the journal Science, by researchers from the University of Gothenburg and the University of Copenhagen, found large patient records tie GLP-1 drugs such as semaglutide and tirzepatide to fewer dementia diagnoses.
- Yet in Novo Nordisk's EVOKE and EVOKE+ phase 3 trials, semaglutide did not slow Alzheimer's itself, cutting nerve-damage markers by only about 10 percent against about 30 percent for drugs proven to slow the disease.
- Popular weight-loss drugs are linked to a lower risk of dementia, but a major trial found they did not slow Alzheimer's disease once it had started.
- A review in the journal Science, by researchers from the University of Gothenburg and the University of Copenhagen, found large patient records tie GLP-1 drugs such as semaglutide and tirzepatide to fewer dementia diagnoses.
- Yet in Novo Nordisk's EVOKE and EVOKE+ phase 3 trials, semaglutide did not slow Alzheimer's itself, cutting nerve-damage markers by only about 10 percent against about 30 percent for drugs proven to slow the disease.
Popular weight-loss drugs are linked to a lower risk of dementia, but a major trial found they did not slow Alzheimer's disease once it had started. A review in the journal Science, by researchers from the University of Gothenburg and the University of Copenhagen, found large patient records tie GLP-1 drugs such as semaglutide and tirzepatide to fewer dementia diagnoses. Yet in Novo Nordisk's EVOKE and EVOKE+ phase 3 trials, semaglutide did not slow Alzheimer's itself, cutting nerve-damage markers by only about 10 percent against about 30 percent for drugs proven to slow the disease. The authors say the drugs may help most when started early, before serious damage sets in — promising, but not proven.
Popular weight-loss drugs are linked to a lower risk of dementia, but a major trial found they did not slow Alzheimer's disease once it had started. A review in the journal Science, by researchers from the University of Gothenburg and the University of Copenhagen, found large patient records tie GLP-1 drugs such as semaglutide and tirzepatide to fewer dementia diagnoses. Yet in Novo Nordisk's EVOKE and EVOKE+ phase 3 trials, semaglutide did not slow Alzheimer's itself, cutting nerve-damage markers by only about 10 percent against about 30 percent for drugs proven to slow the disease. The authors say the drugs may help most when started early, before serious damage sets in — promising, but not proven.
Popular weight-loss drugs are linked to a lower risk of dementia, but a major trial found they did not slow Alzheimer's disease once it had started. A review in the journal Science, by researchers from the University of Gothenburg and the University of Copenhagen, found large patient records tie GLP-1 drugs such as semaglutide and tirzepatide to fewer dementia diagnoses. Yet in Novo Nordisk's EVOKE and EVOKE+ phase 3 trials, semaglutide did not slow Alzheimer's itself, cutting nerve-damage markers by only about 10 percent against about 30 percent for drugs proven to slow the disease. The authors say the drugs may help most when started early, before serious damage sets in — promising, but not proven.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।